🤯 The Therapy That’s Redefining ‘No-Option’ Patients #shorts

Every disruptive therapy comes with a fight.

For DVA, that story was LimFlow, which built a new care paradigm, created new codes, and compelled the field to view “no-option” patients in a completely different light.

Now, after two years off the market in Europe, LimFlow is back with next-gen stents and crossing devices.

Access expands, adoption grows, and the debate gets louder: do we keep DVA only for “no-option” patients, or is it time to start treating poor-option cases too?

Go to the Life of Flow podcast channel and watch the full episode #90.